Healthy volunteers needed to test how two drug versions behave in the body

NCT ID NCT07297693

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial will enroll 60 healthy adults to compare two drug formulations: an orally disintegrating tablet (HIP2503) and a standard tablet (HCP1306). The goal is to see how each is absorbed and processed by the body, and to check for safety. Participants will take a single dose of each in random order, with a break in between. This study is not intended to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HIP2503 (orally disintegrating tablet) and HCP1306 (standard tablet)

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • H plus Yangji Hospital

    Seoul, Gwanak-gu, 08779, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact